We need an abundance of data addressing CNS disease being statistically significantly improved thru MOA of of S1R agonization. This must include inividual impact on each ind by same.
I believe Fritz is going for basket approval of Alz, PDD, and Rett. IF that happens....it paves the way for all other Inds previously discussed being quasi rubber stamped by FDA.
The ramp is steep but incredibly rich for investors who have waited so long having been bewildered by delays.
News 
Market Data 
Discover 
